The U.S. Food and Drug Administration granted broader clearance for GSK’s respiratory syncytial virus (RSV) vaccine, expanding the vaccine’s labeled use and potentially increasing uptake after an initially strong launch. The decision comes as RSV remains a priority target for vaccine makers and follows a period of flattening sales for the shot after launch. GSK’s approval update adjusts the vaccine’s indication and labeling to cover a wider patient population; company statements and regulatory filings provide the details. Broader labeling can directly affect clinician prescribing and payer coverage decisions, with implications for market penetration. For vaccine makers operating in a cautious regulatory environment, the clearance represents a tangible regulatory win. The approval may prompt competitors and payers to reevaluate uptake expectations for RSV prevention in adults and high‑risk groups.